Reckitt Benckiser Group plc (RBGLY) Q1 2026 Sales/Trading Call Transcript

Reckitt reported Q1 2026 core like-for-like net revenue growth of 1.3%, which improves to 3.1% excluding the seasonal business. Growth was driven by high single-digit performance in Emerging Markets, with China and India both posting double-digit gains and Dettol performing strongly in both markets. Results were partly offset by a weak season, competition in Europe, especially autodish, and geopolitical disruptions.

Analysis

This read-through is more interesting for what it implies about category mix than the headline growth rate. The market should treat the ex-seasonal acceleration as evidence that Reckitt’s core portfolio still has pricing power and distribution leverage in higher-growth emerging markets, while the weak seasonal book is acting like a drag that masks underlying momentum. That matters because if seasonality stays depressed for another 1-2 quarters, reported growth can remain mediocre even as the forward earnings base quietly improves.

The second-order winner is likely the supply chain and trade-up ecosystem around China/India health and hygiene, not just Reckitt itself. Double-digit growth in those markets suggests shelf-space allocation is probably shifting toward brands with stronger innovation cadence, which can pressure smaller local competitors first and private-label second; the lagged effect is margin compression for rivals as they spend more to defend share. In Europe, ongoing autodish competition is a signal that price promotions are still doing the work of volume retention, which tends to be a late-cycle warning for category profitability rather than just one-company noise.

The key risk is that geopolitical disruption plus a weak seasonal reset can create a false negative in reported numbers for several months, even if the core trend is intact. If the consumer backdrop softens in North America or Europe over the next 1-2 quarters, management may need to choose between defending share and protecting margin, and that trade-off would likely show up first in gross margin before it shows up in revenue. The consensus may be underestimating how much of the next rerating depends on visible consistency in non-seasonal categories, not just one strong emerging-markets print.

Contrarianly, the setup is not about chasing the quarter; it is about waiting for the market to separate structural EM resilience from cyclical seasonal weakness. If the next update confirms that ex-seasonal growth stays around the low-3% area while seasonals stop deteriorating, the stock could re-rate on better earnings visibility rather than faster top-line growth. If instead Europe remains promotional and North America slows, the right response is not to sell the franchise outright, but to fade near-term optimism and wait for a cleaner entry after estimates reset.

Key Decisions for Investors

• Go long RBGLY on a 3-6 month horizon only on a pullback; risk/reward improves if the stock sells off on headline weakness while ex-seasonal growth remains intact. Target: rerating on better mix visibility; stop if the next print shows nonseasonal growth decelerating below low-single-digits.
• Relative value: long RBGLY / short a European household and personal care peer with heavier exposure to promotional categories and weaker EM mix. The thesis is that EM innovation-driven growth should outlast Europe’s pricing pressure over the next 2 quarters.
• If you want express downside protection, buy short-dated puts into the next trading update only if the stock rallies on headline enthusiasm; the risk is a “good-but-not-great” quarter where seasonal weakness keeps EPS revisions capped.
• Monitor for a pair trade reversal if North American nonseasonal growth inflects lower for two consecutive quarters; that would be the signal that the core story is becoming a margin defense exercise rather than a growth re-acceleration story.